Patents by Inventor Bart Otto Roep

Bart Otto Roep has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220267774
    Abstract: Methods and compositions discussed herein allow for preventing or treating type 1 diabetes (T1D) including directing the breakdown of insulin mRNA.
    Type: Application
    Filed: March 10, 2022
    Publication date: August 25, 2022
    Applicant: CITY OF HOPE
    Inventors: Bart Otto ROEP, Rene Matthijs VAN TIENHOVEN
  • Publication number: 20220073637
    Abstract: Provided herein are, inter alia, anti-CD6 antibody-growth factor complexes including an anti-CD6 antibody portion bound to a growth factor protein (e.g., EGF) through a linker, which may be cleavable by a protease (e.g., diabetic microenvironment specific protease). The compositions provided herein are, inter alia, useful for the treatment of autoimmune diseases (e.g., type I diabetes).
    Type: Application
    Filed: July 1, 2019
    Publication date: March 10, 2022
    Inventors: Jose Enrique Montero CASIMIRO, Bart Otto ROEP, John Charles WILLIAMS
  • Publication number: 20210395329
    Abstract: Provided herein are, inter alia, CD6 targeting CAR-T cell compositions and methods useful for treating autoimmune diseases (e.g., Type I diabetes).
    Type: Application
    Filed: July 1, 2019
    Publication date: December 23, 2021
    Inventors: Jose Enrique Montero Casimiro, Bart Otto Roep, Christine E. Brown
  • Publication number: 20210355448
    Abstract: Provided herein are, inter alia, methods, compositions, and kits for culturing and improving the quality of islet cells. Included are compositions and kits for the ex vivo culture of islets or islet cells as well as methods of making and using the same. Isolated and cultured islets and islet cells are also provided.
    Type: Application
    Filed: June 26, 2018
    Publication date: November 18, 2021
    Inventors: Jose Enrique Montero CASIMIRO, Bart Otto ROEP, Ismail H. AL-ABDULLAH
  • Publication number: 20190330297
    Abstract: The present invention relates to the identification of novel peptides derived from aberrant proteins involved in Type 1 Diabetes mellitus (T1D), also known as defective ribosomal products (DRiPs). In particular the invention relates to epitopes present in DRiPs of the human preproinsulin (PPI) mRNA, its representative peptides and the use thereof in diagnosis, prevention and/or treatment of T1D. Moreover, the inventions relate to antibodies and antisera against the identified epitopes and the use thereof in the diagnosis of T1D.
    Type: Application
    Filed: January 20, 2017
    Publication date: October 31, 2019
    Inventors: Bart Otto ROEP, Menno VAN LUMMEL, Peter Antonis VAN VEELEN, Arnaud ZALDUMBIDE
  • Publication number: 20090226930
    Abstract: The invention provides a purified human 38 kD beta cell antigen consisting of an intrinsic transmembrane protein of insulin secretory granules of beta cells lying in pancreatic islets of Langerhans, which protein contains an epitope recognized by T cell clone 1C6 (ECACC No. 1C6 90050301). The antigen may be used to diagnose diabetes in a patient.
    Type: Application
    Filed: March 13, 2009
    Publication date: September 10, 2009
    Inventors: Bart Otto Roep, Rene Rudolf Pieter de Vries, John Charles Hutton
  • Publication number: 20090023630
    Abstract: The present invention identified novel epitopes from the insulin B chain which is embodied in methods and means for diagnostics and treatment of type 1 diabetes. The epitopes were found in a peptide comprising a fragment of the human insulin B chain. Using HLA-A2 tetramers having the peptide of the invention cytotoxic T-cells were found in peripheral blood cells samples from healthy individuals. The invention demonstrates that these autoreactive CTL directed against insulin B chain are able to destroy insulin producing beta-cells. Moreover, a significant proportion of cytotoxic T-cells from islet transplant recipients with recurrent autoimmunity and loss of insulin production recognized this peptide or analogue thereof. The peptide has a high affinity for the HLA-A2 allele, in particular HLA-A*0201. Based on the novel epitopes according to the invention, diagnostic and therapeutic methods and medicaments for the prevention or treatment of type 1 diabetes are provided.
    Type: Application
    Filed: January 30, 2006
    Publication date: January 22, 2009
    Inventors: Jan Wouter Drijfhout, Bart Otto Roep